Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile

摘要: In a randomized, controlled trial that demonstrated the efficacy of interferon alfa-2b 3 million units three times week for 24 weeks in controlling chronic hepatitic C (non-A, non-B), Sickness Impact Profile (SIP) was used to evaluate impact disease and treatment on health-related quality life (HRQOL). The SIP self-administered by 160 patients before treatment, at end study endpoint. Before with hepatitis scored significantly (P < 0.05) higher (worse) than an historical control group general population mean total score all categories except eating. highest degree impairment observed work, sleep rest, recreation pastimes categories. After who received had significant or = improvement scores. Numerical score, physical psychosocial dimension scores, most individual category Mean scores were unchanged slightly worsened untreated patients. responders (patients serum alanine aminotransferase levels), largest seen work appears be reliable valid instrument describing HRQOL but lacks disease-specificity ability reflect clinically relevant changes. Thus is not best effects C.